Intellia therapeutics reports inducement grants under nasdaq listing rule 5635(c)(4)

Cambridge, mass., july 24, 2024 (globe newswire) -- intellia therapeutics, inc. (nasdaq:ntla), a leading clinical-stage gene editing company focused on revolutionizing medicine with crispr-based therapies, today announced that it awarded inducement grants on july 22, 2024 to its executive vice president and chief financial officer, edward dulac, under intellia's 2024 inducement plan as a material inducement to employment.
NDAQ Ratings Summary
NDAQ Quant Ranking